|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
FI903489A0
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
ES2244066T3
(es)
|
1997-06-24 |
2005-12-01 |
Genentech, Inc. |
Procedimiento y composiciones de glicoproteinas galactosiladas.
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
EP1028751B1
(en)
|
1997-10-31 |
2008-12-31 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
DK2112166T3
(en)
|
1998-12-23 |
2019-02-04 |
Pfizer |
Human monoclonal antibodies to CTLA-4
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
CA2383424C
(en)
|
1999-08-23 |
2011-02-15 |
Gordon Freeman |
Novel b7-4 molecules and uses therefor
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
DE60022369T2
(de)
|
1999-10-04 |
2006-05-18 |
Medicago Inc., Sainte Foy |
Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
|
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
|
EP3225632B1
(en)
|
1999-11-30 |
2020-05-06 |
Mayo Foundation for Medical Education and Research |
Antibodies binding to b7-h1, a novel immunoregulatory molecule
|
|
ATE555794T1
(de)
*
|
2000-02-14 |
2012-05-15 |
Mitsubishi Tanabe Pharma Corp |
Heilmittel gegen hepatitis
|
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
CN102311986B
(zh)
|
2000-10-06 |
2015-08-19 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
RU2321630C2
(ru)
|
2001-08-03 |
2008-04-10 |
Гликарт Биотекнолоджи АГ |
Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
|
|
US20030157108A1
(en)
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
WO2003084569A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Drug containing antibody composition
|
|
CN102911987B
(zh)
|
2002-04-09 |
2015-09-30 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
|
JP4628679B2
(ja)
|
2002-04-09 |
2011-02-09 |
協和発酵キリン株式会社 |
Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
|
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
|
US20040132140A1
(en)
|
2002-04-09 |
2004-07-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
|
WO2004058805A2
(en)
|
2002-12-26 |
2004-07-15 |
Asahi Kasei Pharma Corporation |
T cell activating gene
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
|
US20070134759A1
(en)
|
2003-10-09 |
2007-06-14 |
Harue Nishiya |
Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
|
|
ES2672640T3
(es)
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
|
WO2005097204A1
(ja)
|
2004-04-09 |
2005-10-20 |
Takeda Pharmaceutical Company Limited |
癌の予防・治療剤
|
|
CN1942483B
(zh)
|
2004-04-13 |
2012-09-26 |
弗·哈夫曼-拉罗切有限公司 |
抗p型选凝素抗体
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EA010654B1
(ru)
|
2004-11-23 |
2008-10-30 |
Пи Ай Пи Ко., Лтд. |
Вмонтированная в стену распределительная коробка водоснабжения
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
CN101627054A
(zh)
*
|
2005-07-11 |
2010-01-13 |
马克罗基因公司 |
用人源化抗cd16a抗体治疗自身免疫疾病的方法
|
|
US7842466B1
(en)
|
2005-09-16 |
2010-11-30 |
Celera Corporation |
Colon disease targets and uses thereof
|
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
|
EP2059533B1
(en)
|
2006-08-30 |
2012-11-14 |
Genentech, Inc. |
Multispecific antibodies
|
|
PE20081456A1
(es)
|
2006-10-06 |
2008-11-27 |
Takeda Pharmaceutical |
Anticuerpo monoclonal contra nectina 2
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
JP5933894B2
(ja)
|
2007-09-14 |
2016-06-15 |
アディマブ， エルエルシー |
合理的に設計された、合成抗体ライブラリおよびその使用
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
AR073072A1
(es)
|
2008-08-19 |
2010-10-13 |
Regeneron Pharma |
Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
US20110007023A1
(en)
|
2009-07-09 |
2011-01-13 |
Sony Ericsson Mobile Communications Ab |
Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
KR102810907B1
(ko)
|
2010-07-16 |
2025-05-21 |
아디맵 엘엘씨 |
항체 라이브러리
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
EP2723924A4
(en)
|
2011-06-22 |
2015-03-25 |
Oncocyte Corp |
METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
|
|
EP2768858B1
(en)
|
2011-10-18 |
2018-08-01 |
Emory University |
Antibodies directed against influenza
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
JP2015520192A
(ja)
|
2012-06-06 |
2015-07-16 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｈｉｐｐｏ経路を調節する結合剤およびその使用
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
KR20150090919A
(ko)
|
2012-12-04 |
2015-08-06 |
온코메드 파마슈티칼스, 인크. |
결합제를 사용한 면역요법
|
|
JP2017522311A
(ja)
|
2014-07-16 |
2017-08-10 |
ジェネンテック， インコーポレイテッド |
Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法
|
|
US10227408B2
(en)
|
2015-02-19 |
2019-03-12 |
Compugen Ltd. |
Anti-PVRIG antibodies and methods of use
|
|
CA2997179A1
(en)
*
|
2015-09-02 |
2017-03-09 |
The Regents Of The Unversity Of Colorado, A Body Corporate |
Compositions and methods for modulating t-cell mediated immune response
|
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
|
WO2017221255A1
(en)
|
2016-06-23 |
2017-12-28 |
Memed Diagnostics Ltd. |
Measuring trail by lateral flow immunoassay
|
|
WO2018017864A2
(en)
*
|
2016-07-20 |
2018-01-25 |
Oncomed Pharmaceuticals, Inc. |
Pvrig-binding agents and uses thereof
|
|
CN112274637A
(zh)
*
|
2016-08-17 |
2021-01-29 |
康姆普根有限公司 |
抗tigit抗体、抗pvrig抗体及其组合
|
|
WO2019232484A1
(en)
|
2018-06-01 |
2019-12-05 |
Compugen Ltd |
Anti-pvrig/anti-tigit bispecific antibodies and methods of use
|
|
WO2020018879A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|